Amendments to the claims:

This listing of the claims will replace all prior versions, and listings of claims in the application.

Claim Listing:

1. (Canceled).
2. (Currently Amended) A process for the production of a composition containing at least one coagulation factor, said process consisting of the following steps:
    i. adjusting the pH of a plasma fraction, wherein said plasma fraction contains an initial amount of fibronectin and at least one coagulation factor, contains NaCl or KCl at a concentration of 100 – 200 mM and is characterized by an ionic strength below 500 mM, to a value between pH 4.7 and pH 5.3 so as to form a precipitate comprising 70% to 99% of the initial amount of fibronectin and a supernatant containing said at least one coagulation factor,
    ii. removing the fibronectin precipitate formed in step (i) to thereby yield a composition containing at least one coagulation factor; and
    iii. ~~treating the composition obtained in step (ii) to yield~~ **purifying the** at least one ~~purified~~ coagulation factor **from the composition obtained in step (ii),**

    wherein steps (i) and (ii) are performed at a temperature that ranges from 20°C to 25 °C.
3. (Canceled)
4. (Previously Presented) The process according to claim 2, characterized in that the ionic strength of the plasma fraction is below 300 mM.
5. (Previously Presented) The process according to claim 2, characterized in that the ionic strength of the plasma fraction is below 200 mM.
6. (Previously Presented) The process according to claim 2, wherein removing step (ii) consists of stirring the plasma fraction for at least 10 minutes.
7. (Previously Presented) The process according to claim 2, characterized in that the majority of the fibronectin precipitate is separated by means of an agitator blade of a stirrer.

8. (Previously Presented) The process according to claim 2, characterized in that the plasma fraction initially contains fibronectin at a concentration of at least 0.1 g per liter.

8. (Canceled)

9. (Previously Presented) The process according to claim 2, characterized in that the plasma fraction initially contains glycine at a concentration below 500 mM.

10. (Previously Presented) The process according to claim 2, characterized in that the plasma fraction initially contains glycine at a concentration below 200 mM.

11. (Previously Presented) The process according to claim 2, characterized in that the plasma fraction initially contains glycine at a concentration of 50 to 200 mM.

12. (Previously Presented) The process according to claim 2, characterized in that the plasma fraction initially contains glycine at a concentration of 100 to 150 mM.

13. (Previously Presented) The process according to claim 2, characterized in that the plasma fraction is dissolved cryoprecipitate.

14. (Previously Presented) The process according to claim 14, characterized in that the dissolved cryoprecipitate is previously purified by (a) treatment with aluminum hydroxide, (b) treatment with a solvent and/or a detergent, and (c) anion exchange chromatography.

15. (Canceled)

16. (Previously Presented) The process according to claim 2, characterized in that the at least one coagulation factor is von Willebrand factor.

17. (Canceled)

18. (Canceled)

19. (Canceled)

20. (Canceled)

21. (Canceled)

22. (Canceled)

24. (Previously Presented) The process according to claim 2 , wherein the fibronectin precipitate obtained in step (i) contains at least 90% of the initial amount of fibronectin.